Compare Byrna Technologies Inc (BYRN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs ResMed Inc. — how do they compare? Byrna Technologies Inc trades at $4.23 (market cap $106.74M), while ResMed Inc. trades at $225.19 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 305.5× Byrna Technologies Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | RMD | |
|---|---|---|
Market Cap | $106.74M | $32.61B |
Sector | Technology | Health |
52-Week High | $27.63 | $293.73 |
52-Week Low | $3.18 | $182.82 |
Enterprise Value | $98.35M | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.25, down 12.37% on the day, reflecting investor reaction to recent earnings misses and revenue declines. The stock shows a bullish technical signal with strong moving average support, but fundamentals are mixed with a negative net income margin of -3.39% and ROE of -6.3% for 2026. Recent management changes and strategic acquisitions aim to revitalize growth amid sales challenges highlighted in Q2 2026 results.
The outlook remains cautious due to execution risks in marketing turnaround and competitive pressures. Analyst consensus is 71% buy, but investors face volatility from ongoing investigations and weak quarterly performance. Upside depends on successful brand repositioning and retail expansion under new leadership.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
